titre

A socio economic problem

Addiction is a huge
problem we try to solve.
The market is more than 3 billion USD and involves more than 35M people worldwide

Read More

Innovation research and development

With 20 years of experience,
we have developed new strategies to solve addiction problems

Read More

An effective treatment

Today, there is no real
solution to addiction.
Our first product,
KT-110,is a true chance of treatment.

Read More

European funds

Exceptional participation from Europe to finance clinical trials

Read More

Our mission : overcome the global challenge of addiction (alcohol, tobacco, cocaine, opioids… )

Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people. Indeed, addiction (alcohol, tobacco, gambling...) is becoming a serious socio-economic problem and for the sole US market, treatment of these pathologies reached $3 billion in 2013. Nevertheless, to date, few therapeutic agents are available and efficient on these pathologies of addiction.
Phase 2 study on safety and efficacy of KT-110 in alcohol use disorder is positive. Very High risk level population is likely to be targeted for phase 3 study. FDA accepts TAC reduction as main criterion, which provides consistency between USA and Europe for phase 3 study

Latest events :

The board :

  • Dr Philippe BERNARD

    Kinnov Therapeutics CEO

    20+ years expertise in Med Chem. Founder and Manager of Greenpharma Is author of more than 50 scientific publications and 20 patents.
    Read more

  • Emmanuel de RIVOIRE

    General Manager

    Senior international executive in Pharma industry with 30+ years experience in Europe, Middle East/Africa and Asia. Strong drive, able to manage complex situations. Excellent track record in performances, company transformation and customer culture program. Previous managing experience at Takeda, Nycomed, Roche, GSK, Abbott.
    Read more

  • Dr Fabrice TROVERO

    KT Preclinical R&D manager

    20+ years expertise in CNS pharmacology. Founder of Key-Obs.
    Read more

  • Prof Jean-Pol TASSIN

    KT Scientific advisor

    Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI.
    He is also President of scientific advisory board of MILDT. Member of scientific committee of the European Observatory of Drugs and Toxicomanies.
    He is Laureate for the Prize of the European College of Neurospsychopharmacology (September 2009) for his work and new hypothesis of neurobiological mechanisms of addiction.
    Read more

  • Prof Alain PUECH

    KT clinical project director

    Ph. D. in Pharmacology and a Medical Doctor and has held a number of key positions in his over 30 year career in the pharmaceutical industry including :
    • Professor at the CHU Pitié-Salpétrière(1971-1997).
    • Manager of the International development at Sanofi -Synthelabo (1997-2003).
    • Chief Scientific Officer France Sanofi Aventis (2003-2006).
    He is currently working as a Consultant to industry since 2007.
    Read more

  • Prof Bernard PAU

    KT Business development advisor

    Professor in Immunology and Biotechnology at the University of Montpellier (Faculty of Pharmaceutical sciences); has pioneered in France the transfer of innovation by bridging the gap between academic research and industry in the fields of drug discovery, diagnostic tests and biotechnology; former director of the department of Life sciences at CNRS; formerly with Sanofi Pharmaceutical Group; co-founder of two startup companies: Innodia and I2T; co-author of more than 140 scientific publications and patents; inventor of innovative worldwide marketed diagnostic tests.
    Read more

  • Dr Sylvain YON

    KT Business development advisor

    Sylvain Yon, Ph.D. is the Deputy CEO of Theraclion (www.theraclion.com). In this role, he leads both the research & development efforts of the company and the business expansion on the Asian markets. Sylvain Yon is a co-founder of Echosens, where he headed engineering activities until 2008. He then successfully handled the company’s acquisition by a major player in the Chinese health industry, before joining Theraclion. He is also the founder of several companies in the fields of acoustics and the Internet
    Read more

  • Lucas Biela

    Kinnov Therapeutics Clinical Project Manager

    14+ years of experience in clinical research. Previous experience at Parexel, Onxeo, Danone Research, DBV Technologies
    Read more